Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 in Eosinophilic Gastritis and/or Gastroenteritis (ENIGMA)
NCT03496571Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lirentelimab in eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), sponsored by Allakos Inc.. Started Jul 2018; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic gastroenteritis (EGE)
Beyond the preview
Go deeper on NCT03496571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496571.